Navigation Links
QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy
Date:5/5/2008

ved patient outcomes. The company intends to directly commercialise its products in the US and seek strategic partnerships abroad. QRxPharma's lead compound, Q8003IR, successfully completed a Phase 3 study and met primary endpoints. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information: http://www.QRxPharma.com


'/>"/>
SOURCE QRxPharma
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
3. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
4. Immunosyn Corporation Releases SF-1019 Study Results
5. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
6. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
7. CEL-SCI Corporation Releases Letter to Shareholders
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
10. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
11. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...tCall/--Pharmasset,Inc.(Nasdaq: VRUS )announcedtod...SWX:ROG.VX;RO.S,OTCQX:RHHBY),willcontinuefortherem...rialofRG7128,afirst-in-classnucleosideanalogpolyme...us(HCV)infection.Thedecisionwasreachedafteraschedu...C)ofallavailablesafetydatafromthefirstcohortofappr...
(Date:11/23/2009)...irstCall/--Oceanside Pharmaceuticals ,partofValean...nnouncedthatithasnowlaunchedchlordiazepoxidehydroc...versionofLibrax®.Oceansidehasreceiveditsfirst...#174;genericmarket. ,, "Valeant,sOceansideunith...ssuccessfullaunchanddistributionof5%fluorouracil,V...
(Date:11/23/2009)...ancedSterilizationProducts(ASP),aleadingglobalinfe...cquisitionbyitsFrenchaffiliate,ApsisS.A.S.,ofGlost...ectionprocessesandtechnologiestopreventhealthcare-...closed. ,, GlosterEuropedesignsandmarketsaninno...infectionofpatientenvironmentssuchashospitalandope...
Breaking Medicine Technology:Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Oceanside Pharmaceuticals Announces Launch of Librax(R) AG 2ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities 2Grant received for eye disorder research 50639 1Grant received for eye disorder research 50639 2FDA Approves Multaq 28R 29 for Patients with Atrial Fibrillation or Atrial Flutter 50636 1FDA Approves Multaq 28R 29 for Patients with Atrial Fibrillation or Atrial Flutter 50636 2FDA Approves Multaq 28R 29 for Patients with Atrial Fibrillation or Atrial Flutter 50636 3FDA Approves Multaq 28R 29 for Patients with Atrial Fibrillation or Atrial Flutter 50636 4FDA Approves Multaq 28R 29 for Patients with Atrial Fibrillation or Atrial Flutter 50636 5FDA Approves Multaq 28R 29 for Patients with Atrial Fibrillation or Atrial Flutter 50636 6FDA Approves Multaq 28R 29 for Patients with Atrial Fibrillation or Atrial Flutter 50636 7Lixte Biotechnology Holdings Lead Compound LB 1 2 Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models 12880 1Lixte Biotechnology Holdings Lead Compound LB 1 2 Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models 12880 2Lixte Biotechnology Holdings Lead Compound LB 1 2 Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models 12880 3
...t. 9 The Wellion Linus Blood Glucose,Monitoring S...curacy,testing, recently received certification by...ic Research TNO ("TNO"). TNO is an independent gro...cts medical devices. The,Wellion Linus Blood Gluco...O approval is a testament to the quality and accur...
...tential for Correcting Devastating Genetic Disease...,a mouse brain well connected to other areas, rese...o the entire brain -- after one injection of,gene ...ed in people,researchers may have a potential meth...vastating congenital human neurological disorders,...
Other Medicine Technology:WaveSense Blood Glucose Meter One of Few Brands to Pass Rigorous TNO Tests 2One Shot of Gene Therapy Spreads Through Brain in Animal Study 2One Shot of Gene Therapy Spreads Through Brain in Animal Study 3
(Date:11/23/2009)..., MAYWOOD, Il. -- A Loyola University Health Syst...betics is morbidly obese -- approximately 100 poun...at 62.4 percent of U.S. adults with Type 2 diabete...Among African American adults with Type 2 diabetes...d obesity among people with diabetes is increasing...
(Date:11/23/2009)..., Alzheimer,s disease is caused by the build-up o...eliminating the protein has been the focus of almo...tating neurodegenerative condition. , But that m...Tel Aviv University,s Department of Physiology and...cent research demonstrates that amyloid-beta is al...
(Date:11/23/2009)..., Life-Science Focused St...on of Marketing and Communication Professionals ,...r 23, 2009 -- LaVoie Group, a life science-focused...that it has received the 2009 MarCom Gold Award in... and judged by the Association of Marketing and Co...
(Date:11/23/2009)...,, LOSANGELES,Nov.23/PRNewswire-FirstCall/--...ythatitsproprietarybrandsof MD@Hand ,target=,_blan...e=, MD@Hand ,target=,_blank,title=, MD@Hand ,> MD@...> MD@Hand ,target=,_blank,title=, MD@Hand ,targe...ank,title=, MD@Hand ,target=,_blank,title=, MD@Han...
(Date:11/23/2009)...,, NurturReceivesAccreditationforFivePopula...ewswire-USNewswire/--ThePopulationHealthImpactInst...asedtoannouncedthatPHII,sBoardofDirectorshasapprov....0(H-TAP(TM))aftertwoyearsofdevelopment.Nurtur(TM)...CTisthefirstorganizationtoreceivetheH-TAPaccredita...
Breaking Medicine News(10 mins):Health News:Diabetics show alarming increase in morbid obesity 2Health News:Upending textbook science on Alzheimer's disease 2Health News:LaVoie Group Wins 2009 MarCom Gold Award for Rockwell Medical Homepage Redesign 2Health News:LaVoie Group Wins 2009 MarCom Gold Award for Rockwell Medical Homepage Redesign 3Health News:ISCR Becomes Instant Player in the Obamacare EMR/Cost Savings Sweepstakes 2Health News:ISCR Becomes Instant Player in the Obamacare EMR/Cost Savings Sweepstakes 3Health News:ISCR Becomes Instant Player in the Obamacare EMR/Cost Savings Sweepstakes 4Health News:ISCR Becomes Instant Player in the Obamacare EMR/Cost Savings Sweepstakes 5Health News:ISCR Becomes Instant Player in the Obamacare EMR/Cost Savings Sweepstakes 6Health News:ISCR Becomes Instant Player in the Obamacare EMR/Cost Savings Sweepstakes 7Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 2Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 3
...health probelm in the U.S. A U.S. government surve...h drug addiction// problems will double to approxi... 2.5 million Americans have been said to have enco... partly blamed for the present trend, and an incre...
...ch they say may fight two dangerous germs that bed...cientist at Merck Research Laboratories and his co...roducts, including samples of soil and leaf debris...staph an infection known as that can cause pneum...
...unch its fifth report card on indigenous health, f...Victorian// Aboriginal Health Service in the Melbo...ginal prisoners need immediate access to national ...compared with 0.3 per cent of people from non-indi...
...aid that the government will try to do a balancing...e.// Arjun Singh said in the parliament "Th...roposed. What we can try to do is make efforts to ...reservations and now the IIT’s are also planning t...
...troducing health smart cards to ensure better moni...//r HIV/AIDS, Minister of State for Health and Fam..."Feasibility studies are being conducted for imple...ar at the Ram Manohar Lohia Hospital and the LRS I...
...s Population Fund (UNFPA) Thoraya A Obaid said tha...rs, but it still has many challenges to address in... She said that in population controlling, red...adesh has showed remarkable progress over the year...
Other Medicine News:Health News:The Australian Medical Association To Focus On Health Of Aborigines 2Health News:Arjun Singh Softens Stand on Quota But says Reservation Irrevocable 2Health News:Government Considering Of Issuing ‘Smart Cards’ For HIV/AIDS Patien 2Health News:Bangladesh Progressing But Must Yet Face Challenges In Health Sector 2
...th factor binding protein-2 (IGFBP-2) is one of si...roposed) which specifically bind and modulate the ...of IGFBP-2 for IGF-II is estimated to be significa...in regulation of IGF-II action. Studies in the fet...
...ric proteins that suppress the secretion of FSH (f...nhibin consists of two distinct chains, or subunit...sists of the alpha-subunit and betaA-subunit. Inhi...nit. Only the dimeric forms of the molecule, conta...
...tor II (IGF-II) is a 7.5 kDa peptide which is secr...ave mitogenic and metabolic actions involved in ce...by binding to target cell receptors. IGF-II binds ...monomeric protein which also serves as the recepto...
...asma protein A (PAPP-A) is a large placenta-derive...centrations by placental trophoblast cells, and is...ing concentrations throughout gestation until deli...e measurable levels have been found in non-pregnan...
Medicine Products: